China SXT Pharmaceuticals Announces TCM Homologous Supplements Production

China SXT Pharmaceuticals, a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces, announced that it has begun the production of TCM Homologous Supplements, a classification of health-supporting food used traditionally in China as TCM but which are also consumed as food.

The Company recently reconstructed and assembled an 850-square-meter facility and received a “Food Manufacturing Certificate” issued by the local Food and Drug Administration, which granted the Company permission to produce TCMHS. The scope of production includes “Substitute Teas,” made of TCMHS plants, and “Solid Beverages,” a kind of granule produced through extraction of TCMHS materials.

The Company has successfully developed 42 substitute tea and 4 solid beverage products. The 4 solid beverage products were commercially launched in April 2019, and the commercial launch for the 42 substitute tea products is scheduled for October 2019.

Mr. Feng Zhou, Chief Executive Officer and Director of China SXT, commented, “We are excited about our strategic expansion into the ‘Big Health’ industry being promoted by the Chinese government. Through introducing the new TCMHS products, we will expand our customer base and promote our brand. By supplementing our core TCMP product line, we will fuel sustainable growth for our shareholders in the years to come.”